
Intelligencia AI
Intelligencia AI
Intelligencia AI
Applying machine learning in drug development
Applying machine learning in drug development
Software Development
Software Development
New York
New York
US
US
51–200 employees
51–200 employees
January 2017
January 2017
Overview
Overview
Intelligencia AI uses artificial intelligence to de-risk drug development. Our platform focuses on estimating the risk of clinical trials, and interpreting the multitude of factors that contribute to that risk. We bridge the gap between innovation and risk reduction, with the ultimate goal of bringing novel therapies to patients faster.
Our interdisciplinary team of software engineers, AI practitioners, scientists, and drug developers combines and interprets disparate data across the life sciences industry. Our platform offers a suite of functionalities that provide unprecedented data clarity and Machine-Learning predictions to enable critical decision-making.
We currently work with several of the largest global pharmaceutical companies as well as mid-size and smaller biotechnology companies.
Diseases will impact nearly every individual. At Intelligencia AI, we work to make a difference.
Intelligencia AI uses artificial intelligence to de-risk drug development. Our platform focuses on estimating the risk of clinical trials, and interpreting the multitude of factors that contribute to that risk. We bridge the gap between innovation and risk reduction, with the ultimate goal of bringing novel therapies to patients faster.
Our interdisciplinary team of software engineers, AI practitioners, scientists, and drug developers combines and interprets disparate data across the life sciences industry. Our platform offers a suite of functionalities that provide unprecedented data clarity and Machine-Learning predictions to enable critical decision-making.
We currently work with several of the largest global pharmaceutical companies as well as mid-size and smaller biotechnology companies.
Diseases will impact nearly every individual. At Intelligencia AI, we work to make a difference.
Key personnel profiles
Key personnel profiles
Key personnelS
Dimitrios Skaltsas
Co-Founder & CEO, Intelligencia AI: De-risking drug development| Inc. 5000 x2| Executive in Residence, AI at INSEAD
view profile

Hiring Trend
Hiring Trend
TOTAL hires
TOTAL hires
7
7
Employee Growth
Employee Growth
TOTAL EMPLOYEES
TOTAL EMPLOYEES
110
110
6m GROWTH
6m GROWTH
-4%
-4%
1y GROWTH
1y GROWTH
-4%
-4%
Employee Distribution & Department Growth
Employee Distribution & Department Growth
TOTAL EMPLOYEES
TOTAL EMPLOYEES
110
110
6m GROWTH
6m GROWTH
1y GROWTH
1y GROWTH
Department distribution
Department distribution
Department distribution
DEPARTMENT
6m GROWTH
1y GROWTH
Research
Research
Research
0%
0%
0%
-11%
-11%
-11%
Engineering
Engineering
Engineering
-17%
-17%
-17%
-12%
-12%
-12%
Information Technology
Information Technology
Information Technology
0%
0%
0%
25%
25%
25%
Business Development
Business Development
Business Development
-9%
-9%
-9%
-9%
-9%
-9%
Product Management
Product Management
Product Management
0%
0%
0%
0%
0%
0%
Web Engagement
pages per visit
pages per visit
1.7
1.7
monthly visits
monthly visits
4,213
4,213
Web Traffic by Country
Web Traffic by Country
United States
66.1%
United States
66.1%
India
33.9%
India
33.9%
Web Traffic Sources
Web Traffic Sources
monthly visits
4,213
Direct
27.1%
Direct
27.1%
Search
37.5%
Search
37.5%
Social
7.8%
Social
7.8%
Referrals
7.5%
Referrals
7.5%
AI
2.3%
AI
2.3%
funding round
funding round
1
total funding raised
total funding raised
$12M
last round type
last round type
Series A
last round amount
last round amount
$12M
announced on
announced on
$12M
funding round
1
total funding raised
$12M
last round type
Series A
last round amount
$12M
announced on
$12M
lead investors
lead investors
lead investors
MTIP, Big Pi Ventures, Synetro Group, ZS, Bantam Group, ByTheTower
MTIP, Big Pi Ventures, Synetro Group, ZS, Bantam Group, ByTheTower
Recent News & Articles
Recent News & Articles






